Stonepine Capital Management LLC Boosts Holdings in Surrozen, Inc. (NASDAQ:SRZN)

Stonepine Capital Management LLC lifted its stake in Surrozen, Inc. (NASDAQ:SRZN) by 66.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,000 shares of the company’s stock after purchasing an additional 43,916 shares during the quarter. Surrozen accounts for approximately 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 24th biggest position. Stonepine Capital Management LLC owned approximately 3.43% of Surrozen worth $1,318,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of SRZN. CVI Holdings LLC purchased a new stake in shares of Surrozen during the 2nd quarter valued at about $711,000. Nantahala Capital Management LLC purchased a new stake in shares of Surrozen during the 2nd quarter valued at about $2,050,000. Finally, Armistice Capital LLC purchased a new stake in shares of Surrozen during the 2nd quarter valued at about $2,080,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen Stock Up 3.8 %

Shares of NASDAQ SRZN traded up $0.36 during midday trading on Wednesday, reaching $9.74. 1,991 shares of the stock traded hands, compared to its average volume of 16,001. Surrozen, Inc. has a one year low of $6.00 and a one year high of $16.19. The company’s 50 day moving average is $10.20 and its 200 day moving average is $9.71.

Surrozen (NASDAQ:SRZN) last released its earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The business had revenue of $10.00 million during the quarter. As a group, equities analysts predict that Surrozen, Inc. will post -7.16 EPS for the current fiscal year.

Surrozen Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.